Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
The active ingredient, orforglipron, was originally discovered by Chugai Pharmaceutical Co., Ltd
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity
The study was approved by the Institutional Review Board of Plastic Surgery Hospital, Chinese Academy of Medical Sciences, and the reference number for their judgment is IRB2024-364
The confirmatory secondary endpoints included the change in the 6-min walking distance, a hierarchical composite of death and heart failure events
65 Using goal body weight for calculations (e.g., 0.7g/lb or 1.0-1.5 g/kg of goal weight) can also be a useful approach
Long-term studies are needed to confirm these findings
US$ 29.53
US$ 28.06
US$ 25.86
US$ 21.56
US$ 24.38
US$ 27.86
